PECAM1 and neoplasm: Baicalein inhibits tumor cell development by modulating different metabolic signaling pathways, as well as decreasing tumor growth and metastasis rates, significantly decreasing CD31 (an endothelial cell marker) and α-smooth muscle actin (α-SMA, a parietal cell marker) expression and inducing cell death in tumor tissues [51].